Oncology Pipeline Update
Here is an update on Oncology Pipelines courtesy of Linda Pullan (lpullan@msn.com), a consultant who follows the sector. www.PullanConsulting.com Pfizer (PFE), Roche (RHHBY) and Novartis (NVS) are predicted to launch the most drugs. Some Pharma Companies Need to In-License in Oncology Now by...
Supergen(SUPG) in a Rally Mode at $2.43;Reiterate Buy
Supergen (SUPG) has been moving up steadily over the past few days since its low in the $2.10+ range this week.SUPG is in the Rayno Life Science Portfolio. The April 15,2010 high was $3.72.The balance sheet is strong with over $100M in cash,Shareholder Equity of $106M and no debt. Market Cap is...
Post-ASCO Doldrums
Market Risk is Up-Speculation Is Off-Look for Value The news out of ASCO was not that new and exciting but it is even harder to find anything positive to write about three weeks later. Investors are "hiding out". The overall market has cooled down from the recent rally and macro news has not...
Multinational Drug Stocks and the Euro ETF(FXE)
Large Cap drug stocks have rallied over the past week as the market was up overall but also because the Euro was up 3% over the past 4 days. Is the correlation there? Well look at these charts tracking drug multinationals and the Euro through the ETF FXE. Pfizer (PFE) and Abbott (ABT) track...
Genomics Boom Boosts Sales of Research Tools
Genomics and Medicine: transformative therapies are coming but diagnostic breakthroughs will lead the way Ten years after the start of the Human Genome Project we have learned a lot about the links between genetics and disease but few direct cures have emerged. The biotech Company Human Genome...